Ranpirnase

Last updated
Ranpirnase
2I5S.png
Crystallographic structure of ranpirnase in complex with RNA. [1]
Identifiers
Organism Rana pipiens
Symboln/a
PDB 2I5S
UniProt P85073
Other data
EC number 4.6.1.18
Search for
Structures Swiss-model
Domains InterPro

Ranpirnase is a ribonuclease enzyme found in the oocytes of the Northern Leopard Frog (Rana pipiens). Ranpirnase is a member of the pancreatic ribonuclease (RNase A) protein superfamily and degrades RNA substrates with a sequence preference for uracil and guanine nucleotides. Along with amphinase, another leopard frog ribonuclease, Ranpirnase has been studied as a potential cancer and antiviral treatment due to its unusual mechanism of cytotoxicity tested against transformed cells and antiviral activity. [2]

Contents

Ranpirnase was originally discovered by scientists at TamirBio, [3] a biotechnology company (formerly Alfacell Corporation), where it was tested in preclinical assays [4] and in clinical trials under the name Pannon or Onconase, and TMR004. The mechanism of action of ranpirnase has been attributed to the RNA interference pathway, potentially through cleaving siRNA molecules; [5] to cleavage of transfer RNA; [2] and to interference with the NF-κB pathway. [6] Currently (as of March 2020) Ranpirnase is in clinical trials as a potential antiviral. [7]

EC number

The EC system, or enzyme classification system was created to both standardize enzyme names, as well as allow for association of enzyme reaction type and function.  The EC number for Ranpirnase is EC 4.6.1.18, [8] but was previously EC 3.1.27.5. [9]  This means that ranpirnase is in class 4, subclass 6, sub-subclass 1, and serial #18.  Class 4 are considered lyases, while subclass 4.6.1 further classifies the enzyme as a phosphorus-oxygen lyase.  Ultimately, ranpirnase can be classified as a pancreatic ribonuclease. [8]  

Reaction pathway

The reaction pathway of ranpirnase is initiated by the enzyme adhering to the surface of the targeted cell.  Ranpirnase then penetrates and enters the cell through energy-dependent endocytosis.  Once in the cell, ranpirnase is directed via the Golgi apparatus to the cytosol, where the enzyme then can selectively break down tRNA, while ignoring rRNA and mRNA.  Ranpirnase degrades tRNA by facilitating the cleavage of the P-O5’ bond found in RNA, specifically on the 3’ side of pyrimidine nucleosides.  As a result of this RNA degradation process, protein synthesis is hindered.  This inhibition of protein synthesis contributes to the cytostatic and cytotoxic effects of ranpirnase. [10]

Structure

Ranpirnase is found in the oocytes of Rana pipiens, also known as the Northern leopard frog.  These oocytes have two similar variations of pancreatic ribonuclease A, which both exhibit cytostatic and cytotoxic properties. Ranpirnase contains 104 amino acid residues, making it the smallest identified member of the RNase A superfamily.  Overall, ranpirnase is considered small single chain protein that has a molecular weight around 12,000 Da.  Once ranpirnase was isolated from the oocytes, it was discovered that ranpirnase is polymorphic at amino acid position 25.  Specifically, this position has historically been occupied by Thr amino acids, but Ser amino acids have also been identified.  This replacement, however, does not appear to change the function of the enzyme.  Additionally, ranpirnase contains 4 disulfide bonds that give the enzyme high heat stability. [11]

Function

Once in the cell, ranpirnase plays both a cytostatic and cytotoxic role.  Cytostatically, ranpirnase halts the cell cycle in G1, but simultaneously acts as a cytotoxin.  There is evidence indicating that the damage caused to tRNA is irreversible and can serve as a pro-apoptotic signal, however this appears to be dependent on additional enzymes that assist in programmed cell death.  Ranpirnase appears to be most active and effective against tumor cells compared to normal cells.  Within these tumor cells, ranpirnase activates a signal-transduction pathway called stress-activated protein kinase or SAPK.  SAPK1 contains JNK-1 and -2 alleles that are targeted and disturbed by ranpirnase.  These JNKs play a significant role as moderators of the cytotoxic effects induced by ranpirnase.  Ultimately, ranpirnase appears to be more apoptotic in cancer cells due to the induction of multiple pro-apoptotic pathways. [10]

Known crystal structures

The crystal structure of ranpirnase contains a segment that encompasses the beginning of a helix.  This is where the main chain assumes a strained conformation leading to noticeable deviations from planarity within the peptide bonds of this enzyme.  Specifically, the peptide bonds of Ser39, Arg40, and Pro41 experience ω dihedral angles of 160.0, 192.1, and 193.5°, respectively.  The orientations of the side chains of Arg40 and Glu42 are clearly defined, and Arg40's guanidino group aligns itself with a sulfate ion. [9]

Known active sites

Ranpirnase's active site encompasses a catalytic triad that commonly found in the RNase A superfamily.  This catalytic triad consists of His10, Lys31, and His97.  In addition to the common catalytic triad, ranpirnase has two extra active-site residues: Lys9 and an N-terminal pyroglutamate residue.  These additional active sites are created within the endoplasmic reticulum through the co-translational cyclization of its encoded glutamine. [12]

Structure tied to function

The structure of ranpirnase does appear to have an impact on its function.  Specifically, studies suggest that ranpirnase uses Coulombic interactions as well as a hydrogen bonding system to adjust substrate specificity. Additionally, it has been seen that intentional changes in amino acid replacements can also modify substrate specificity.  Studies have also investigated the structural characteristics that underlie the reduced catalytic activity of ranpirnase.  This decreased catalytic activity is associated with low affinity for substrate.  A solution to this appears to be undergoing T5R substitution.  A T5R substitution is engineered to establish a successful Coulombic interaction between ranpirnase and a phosphoryl group in RNA.  This then resulted in a twofold enhancement of ribonucleolytic activity. [13]

Related Research Articles

<span class="mw-page-title-main">Enzyme</span> Large biological molecule that acts as a catalyst

Enzymes are proteins that act as biological catalysts by accelerating chemical reactions. The molecules upon which enzymes may act are called substrates, and the enzyme converts the substrates into different molecules known as products. Almost all metabolic processes in the cell need enzyme catalysis in order to occur at rates fast enough to sustain life. Metabolic pathways depend upon enzymes to catalyze individual steps. The study of enzymes is called enzymology and the field of pseudoenzyme analysis recognizes that during evolution, some enzymes have lost the ability to carry out biological catalysis, which is often reflected in their amino acid sequences and unusual 'pseudocatalytic' properties.

<span class="mw-page-title-main">Ribonuclease</span> Class of enzyme that catalyzes the degradation of RNA

Ribonuclease is a type of nuclease that catalyzes the degradation of RNA into smaller components. Ribonucleases can be divided into endoribonucleases and exoribonucleases, and comprise several sub-classes within the EC 2.7 and 3.1 classes of enzymes.

<span class="mw-page-title-main">Ribonuclease H</span> Enzyme family

Ribonuclease H is a family of non-sequence-specific endonuclease enzymes that catalyze the cleavage of RNA in an RNA/DNA substrate via a hydrolytic mechanism. Members of the RNase H family can be found in nearly all organisms, from bacteria to archaea to eukaryotes.

<span class="mw-page-title-main">Ribonuclease L</span> Enzyme found in humans

Ribonuclease L or RNase L, known sometimes as ribonuclease 4 or 2'-5' oligoadenylate synthetase-dependent ribonuclease, is an interferon (IFN)-induced ribonuclease which, upon activation, destroys all RNA within the cell. RNase L is an enzyme that in humans is encoded by the RNASEL gene.

<span class="mw-page-title-main">Angiogenin</span> Protein-coding gene in the species Homo sapiens

Angiogenin (ANG) also known as ribonuclease 5 is a small 123 amino acid protein that in humans is encoded by the ANG gene. Angiogenin is a potent stimulator of new blood vessels through the process of angiogenesis. Ang hydrolyzes cellular RNA, resulting in modulated levels of protein synthesis and interacts with DNA causing a promoter-like increase in the expression of rRNA. Ang is associated with cancer and neurological disease through angiogenesis and through activating gene expression that suppresses apoptosis.

<span class="mw-page-title-main">Ribonuclease P</span> Class of enzymes

Ribonuclease P is a type of ribonuclease which cleaves RNA. RNase P is unique from other RNases in that it is a ribozyme – a ribonucleic acid that acts as a catalyst in the same way that a protein-based enzyme would. Its function is to cleave off an extra, or precursor, sequence of RNA on tRNA molecules. Further, RNase P is one of two known multiple turnover ribozymes in nature, the discovery of which earned Sidney Altman and Thomas Cech the Nobel Prize in Chemistry in 1989: in the 1970s, Altman discovered the existence of precursor tRNA with flanking sequences and was the first to characterize RNase P and its activity in processing of the 5' leader sequence of precursor tRNA. Recent findings also reveal that RNase P has a new function. It has been shown that human nuclear RNase P is required for the normal and efficient transcription of various small noncoding RNAs, such as tRNA, 5S rRNA, SRP RNA and U6 snRNA genes, which are transcribed by RNA polymerase III, one of three major nuclear RNA polymerases in human cells.

<span class="mw-page-title-main">Bovine pancreatic ribonuclease</span>

Bovine pancreatic ribonuclease, also often referred to as bovine pancreatic ribonuclease A or simply RNase A, is a pancreatic ribonuclease enzyme that cleaves single-stranded RNA. Bovine pancreatic ribonuclease is one of the classic model systems of protein science. Two Nobel Prizes in Chemistry have been awarded in recognition of work on bovine pancreatic ribonuclease: in 1972, the Prize was awarded to Christian Anfinsen for his work on protein folding and to Stanford Moore and William Stein for their work on the relationship between the protein's structure and its chemical mechanism; in 1984, the Prize was awarded to Robert Bruce Merrifield for development of chemical synthesis of proteins.

<span class="mw-page-title-main">Ribonuclease inhibitor</span>

Ribonuclease inhibitor (RI) is a large (~450 residues, ~49 kDa), acidic (pI ~4.7), leucine-rich repeat protein that forms extremely tight complexes with certain ribonucleases. It is a major cellular protein, comprising ~0.1% of all cellular protein by weight, and appears to play an important role in regulating the lifetime of RNA.

<span class="mw-page-title-main">Ribonuclease III</span> Class of enzymes

Ribonuclease III (RNase III or RNase C)(BRENDA 3.1.26.3) is a type of ribonuclease that recognizes dsRNA and cleaves it at specific targeted locations to transform them into mature RNAs. These enzymes are a group of endoribonucleases that are characterized by their ribonuclease domain, which is labelled the RNase III domain. They are ubiquitous compounds in the cell and play a major role in pathways such as RNA precursor synthesis, RNA Silencing, and the pnp autoregulatory mechanism.

<span class="mw-page-title-main">Drosha</span> Ribonuclease III enzyme

Drosha is a Class 2 ribonuclease III enzyme that in humans is encoded by the DROSHA gene. It is the primary nuclease that executes the initiation step of miRNA processing in the nucleus. It works closely with DGCR8 and in correlation with Dicer. It has been found significant in clinical knowledge for cancer prognosis and HIV-1 replication.

<span class="mw-page-title-main">Nuclear RNase P</span>

In molecular biology, nuclear ribonuclease P is a ubiquitous endoribonuclease, found in archaea, bacteria and eukarya as well as chloroplasts and mitochondria. Its best characterised enzyme activity is the generation of mature 5′-ends of tRNAs by cleaving the 5′-leader elements of precursor-tRNAs. Cellular RNase Ps are ribonucleoproteins. The RNA from bacterial RNase P retains its catalytic activity in the absence of the protein subunit, i.e. it is a ribozyme. Similarly, archaeal RNase P RNA has been shown to be weakly catalytically active in the absence of its respective protein cofactors. Isolated eukaryotic RNase P RNA has not been shown to retain its catalytic function, but is still essential for the catalytic activity of the holoenzyme. Although the archaeal and eukaryotic holoenzymes have a much greater protein content than the bacterial ones, the RNA cores from all three lineages are homologous—the helices corresponding to P1, P2, P3, P4, and P10/11 are common to all cellular RNase P RNAs. Yet there is considerable sequence variation, particularly among the eukaryotic RNAs.

<span class="mw-page-title-main">Pancreatic ribonuclease family</span> Class of enzymes

Pancreatic ribonuclease family is a superfamily of pyrimidine-specific endonucleases found in high quantity in the pancreas of certain mammals and of some reptiles.

<span class="mw-page-title-main">Amphinase</span>

Amphinase is a ribonuclease enzyme found in the oocytes of the Northern leopard frog (Rana pipiens). Amphinase is a member of the pancreatic ribonuclease protein superfamily and degrades long RNA substrates. Along with ranpirnase, another leopard frog ribonuclease, amphinase has been studied as a potential cancer therapy due to its unusual mechanism of cytotoxicity tested against tumor cells.

RNase R, or Ribonuclease R, is a 3'-->5' exoribonuclease, which belongs to the RNase II superfamily, a group of enzymes that hydrolyze RNA in the 3' - 5' direction. RNase R has been shown to be involved in selective mRNA degradation, particularly of non stop mRNAs in bacteria. RNase R has homologues in many other organisms.

The degradosome is a multiprotein complex present in most bacteria that is involved in the processing of ribosomal RNA and the degradation of messenger RNA and is regulated by Non-coding RNA. It contains the proteins RNA helicase B, RNase E and Polynucleotide phosphorylase.

<span class="mw-page-title-main">RNASE1</span> Protein-coding gene in the species Homo sapiens

Ribonuclease pancreatic is an enzyme that in humans is encoded by the RNASE1 gene.

<span class="mw-page-title-main">Ribonuclease 4</span> Protein-coding gene in the species Homo sapiens

Ribonuclease 4 is an enzyme that in humans is encoded by the RNASE4 gene.

Bovine seminal RNase (BS-RNase) is a member of the ribonuclease superfamily produced by the bovine seminal vesicles. This enzyme can not be differentiated from its members distinctly since there are more features that this enzyme shares with its family members than features that it possess alone. The research on the question of how new functions arrive in proteins in evolution led the scientists to find an uncommon consequence for a usual biological event called gene conversion in the case of the ribonuclease (RNase) protein family. The most well-known member of this family, RNase A, is expressed in the pancreas of oxen. It serves to digest RNA in intestine, and evolved from bacteria fermenting in the stomach of the first ox. The homologous RNase, called seminal RNase, differs from RNase A by 23 amino acids and is expressed in seminal plasma in the concentration of 1-1.5 mg/ml, which constitutes more than 3% of the fluid protein content. Bovine seminal ribonuclease (BS-RNase) is a homologue of RNase A with specific antitumor activity.

Ribonuclease E is a bacterial ribonuclease that participates in the processing of ribosomal RNA and the chemical degradation of bulk cellular RNA.

<span class="mw-page-title-main">Retroviral ribonuclease H</span>

The retroviral ribonuclease H is a catalytic domain of the retroviral reverse transcriptase (RT) enzyme. The RT enzyme is used to generate complementary DNA (cDNA) from the retroviral RNA genome. This process is called reverse transcription. To complete this complex process, the retroviral RT enzymes need to adopt a multifunctional nature. They therefore possess 3 of the following biochemical activities: RNA-dependent DNA polymerase, ribonuclease H, and DNA-dependent DNA polymerase activities. Like all RNase H enzymes, the retroviral RNase H domain cleaves DNA/RNA duplexes and will not degrade DNA or unhybridized RNA.

References

  1. Lee JE, Bae E, Bingman CA, Phillips GN, Raines RT (January 2008). "Structural basis for catalysis by onconase". Journal of Molecular Biology. 375 (1): 165–177. doi:10.1016/j.jmb.2007.09.089. PMC   2151974 . PMID   18001769.
  2. 1 2 Ardelt W, Shogen K, Darzynkiewicz Z (June 2008). "Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes". Current Pharmaceutical Biotechnology. 9 (3): 215–225. doi:10.2174/138920108784567245. PMC   2586917 . PMID   18673287.
  3. "Tamir Reports Positive Effect Against SARS Virus".
  4. Darzynkiewicz Z, Carter SP, Mikulski SM, Ardelt WJ, Shogen K (May 1988). "Cytostatic and cytotoxic effects of Pannon (P-30 Protein), a novel anticancer agent". Cell and Tissue Kinetics. 21 (3): 169–182. doi:10.1111/j.1365-2184.1988.tb00855.x. PMID   3224365. S2CID   29722939.
  5. Zhao H, Ardelt B, Ardelt W, Shogen K, Darzynkiewicz Z (October 2008). "The cytotoxic ribonuclease onconase targets RNA interference (siRNA)". Cell Cycle. 7 (20): 3258–3261. doi:10.4161/cc.7.20.6855. PMC   2586937 . PMID   18927512.
  6. Nasu M, Carbone M, Gaudino G, Ly BH, Bertino P, Shimizu D, et al. (May 2011). "Ranpirnase Interferes with NF-κB Pathway and MMP9 Activity, Inhibiting Malignant Mesothelioma Cell Invasiveness and Xenograft Growth". Genes & Cancer. 2 (5): 576–584. doi:10.1177/1947601911412375. PMC   3161417 . PMID   21901170.
  7. Clinical trial number NCT03856645 for "OKG-0301 for the Treatment of Acute Adenoviral Conjunctivitis (RUBY)" at ClinicalTrials.gov
  8. 1 2 "Information on EC 4.6.1.18 - pancreatic ribonuclease - BRENDA Enzyme Database". www.brenda-enzymes.org. Retrieved 23 October 2023.
  9. 1 2 Holloway DE, Singh UP, Shogen K, Acharya KR (November 2011). "Crystal structure of Onconase at 1.1 Å resolution--insights into substrate binding and collective motion". The FEBS Journal. 278 (21): 4136–4149. doi:10.1111/j.1742-4658.2011.08320.x. PMC   3397563 . PMID   21895975.
  10. 1 2 Porta C, Paglino C, Mutti L (December 2008). "Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma". Biologics. 2 (4): 601–609. doi: 10.2147/BTT.S2383 . PMC   2727885 . PMID   19707441.
  11. Ardelt W, Shogen K, Darzynkiewicz Z (June 2008). "Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes". Current Pharmaceutical Biotechnology. 9 (3): 215–225. doi:10.2174/138920108784567245. PMC   2586917 . PMID   18673287.
  12. Lee JE, Raines RT (2008). "Ribonucleases as novel chemotherapeutics : the ranpirnase example". BioDrugs. 22 (1): 53–58. doi:10.2165/00063030-200822010-00006. PMC   2802594 . PMID   18215091.
  13. Lee JE, Bae E, Bingman CA, Phillips GN, Raines RT (January 2008). "Structural basis for catalysis by onconase". Journal of Molecular Biology. 375 (1): 165–177. doi:10.1016/j.jmb.2007.09.089. PMC   2151974 . PMID   18001769.